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Background: Adherence to and tolerance of oral adjuvant endocrine therapy (ET) are important to
improve survival for hormone receptor (HR)-positive breast cancer patients. To date, there has been
limited literature discussing this issue in elderly patients. Hereinwe have presented a retrospective study
to analyze the tolerance to and completion rate of ET in a single medical center in Taiwan.
Patients and methods: From 1996 to 2009, a total of 269 female patients over 70 years of age with pri-
mary HR-positive operable breast cancer were registered and analyzed for this study.
Results: In our study, the completion rate was 49.4% for all 269 patients and was 56.7% for those willing
to initiate ET. Of the 72 patients that discontinued ET early but not due to recurrence, 9.7% had well-
documented ET-related adverse events, 33.3% refused to undergo ET but remained in follow-up, 44.4%
did not undergo ET because of loss of follow-up before a complete ET period, and 12.5% of the patients
discontinued ET arising from other medical conditions. The switch therapy, tamoxifen followed by
aromatase inhibitor, showed a greater completion rate, compared with upfront tamoxifen or aromatase
inhibitor.
Conclusions: The completion rate for patients who underwent oral ET in our study was similar to
previous studies. The switch method of adjuvant oral endocrine therapy demonstrated a better toler-
ance and adherence in elderly breast cancer patients, compared with tamoxifen or aromatase inhibitor
alone.
Copyright © 2016, The Chinese Oncology Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Adjuvant oral endocrine therapy (ET) demonstrates signiﬁcant
survival beneﬁts in postmenopausal breast cancer patients with
positive hormone receptor (HR).1e4 However, some of the patients
taking either tamoxifen or aromatase inhibitor (AI) experienced ET-
related adverse events. For tamoxifen, common adverse events
include hot ﬂash, endometrial thickening, vaginal spotting or
thromboembolic events.4e6 For AI, arthralgia and loss of bone
density may occur.1,2 These adverse events may affect patients'nd Oncology, Department of
Linkou Branch, No.5, Fusing
g).
ncology Society.
Society. Production and hosting byadherence to a daily pill regimen, not to mention further medica-
tion intake for the next ﬁve years.
Elderly patients, especially those in excess of 70 years of age, are
often quite fragile7; such fragility may be secondary to aging or
comorbidity. In this “susceptible” patient population, the negative
inﬂuence of ET-adverse events on patient adherence to a medica-
tion regimen can be elevated.8,9 This may occur because the drug
toxicities could more signiﬁcantly impact elderly patients with a
declining quality of life, compared with the general population.
Therefore, the tolerance of and adherence to adjuvant oral endo-
crine therapy has become an important issue as we continue to
treat this patient population and hopefully improve survival.
However, there has been limited literature discussing this topic.
Therefore, we retrospectively analyzed the completion of and
tolerance to adjuvant oral endocrine therapy in elderly early breast
cancer patients in a single medical center in Taiwan.Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Patients' baseline characteristics.
Characteristics (n ¼ 269) Patient number Percentage (%)
The year of diagnosis
1996e2000 48 17.8%
2001e2005 110 40.9%
2006e2009 111 41.3%
Age
70  Age < 75 147 54.6%
75  Age < 80 79 29.4%
80  Age < 85 29 10.8%
85  Age 14 5.2%
Comorbidities
Diabetes mellitus 81 30.1%
Stroke 20 7.4%
Hypertension 135 50.2%
Heart disease* 23 8.6%
No known systemic disease** 88 32.7%
Stage
I 80 29.7%
II 130 48.3%
III 59 21.9%
Tumor size
T1m-T1b 23 8.6%
T1c 80 29.7%
T2 143 53.2%
T3 and T4 23 8.6%
Nodal status
N0 151 56.1%
N1 64 23.8%
N2 28 10.4%
N3 26 9.7%
Status of hormone receptor (HR)
Positive ER and PR 194 72.1%
Positive ER but negative PR 55 20.4%
Negative ER but positive PR 21 7.8%
Status of human epidermal
receptor-2 (HER2)
Positive HER2 41 15.2%
Negative HER2 201 74.7%
Unknown 27 10.0%
Histologic grade
1 78 29.0%
2 123 45.7%
3 32 11.9%
Unknown status 36 13.4%
Heart disease* includes atrial ﬁbrillation, ischemic heart disease or congestive heart
failure.
No known systemic disease** means no known diabetes mellitus, stroke, hyper-
tension, heart disease, dementia, liver cirrhosis, chronic lung disease (asthma,
chronic obstructive lung disease or bronchiectasis).
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According to the Cancer Registry Databank of Chang Gung Me-
morial Hospital, Linkuo branch, a total of 444 elderly female pa-
tients with primary early breast cancer were treated between 1996
and 2009. These 444 patients were all above 70 years of age and
received curative breast surgery at our institute, either modiﬁed
radical mastectomy or partial mastectomy. Two hundred and sixty-
nine of these patients were classiﬁed as positive HR, deﬁned by
positive estrogen receptor (ER) and/or progesterone receptor (PR).
The pathologic diagnosis of HR-positive primary breast cancer
was conﬁrmed by pathologists, based on the customary criteria at
that time. Axillary lymph node sampling or dissection could be
performed depending upon the surgeon's judgment. Additionally,
adjuvant chemotherapy would be recommended if a high risk of
recurrence was involved.10 The choice of chemotherapy regimens,
such as modiﬁed CMF or anthracycline-based regimens, was also
dependent on the decision of each physician. Adjuvant radio-
therapy would be suggested if certain factors were present
including partial mastectomy, >3 positive lymph node involve-
ment, positive surgical margins, tumor size 5 cm or skin
involvement. Oral endocrine therapy was given for patients with
HR-positive breast tumors, and the choice of tamoxifen or AI again
was based on the decision of the physician. Furthermore, admin-
istration of adjuvant treatment, including chemotherapy, radio-
therapy and ET, would be discussed with the patients and their
families.
We obtained the ages of the patients, the year of diagnosis, TNM
stage, status of ER, PR and HER2 and histologic grading from pri-
mary chart review. The duration of oral endocrine therapy, causes
of discontinuation, and the switches of medications were also
recorded. Data was summarized as N (%) for categorical variables,
and medians with interquartile ranges (IQR; 25e75%) for contin-
uous characteristics. We used the Chi-square test to compare pa-
rameters between different subgroups, and Fisher's exact test for
comparisons with small event numbers. Statistic assessments were
considered as signiﬁcance when the p value was less than 0.05.
SPSS 22.0 software (SPSS Inc., Chicago, USA) was used for statistic
analysis.
3. Results
A total of 269 female elderly patients over the age of 70 were
registered and diagnosed with HR-positive operable primary breast
cancer, with a median age of 75 (IQR 72e78). Themedian follow-up
period was 76.4 months. Only 88 patients (32.7%) had no known
systemic underlying diseases. One hundred and ninety-four pa-
tients (72.1%) had both positive ER and PR, and 55 patients (20.4%)
had positive ER but negative PR. There were 21 patients (7.8%) who
showed positive PR but negative ER. Other patients' baseline
characteristics, including the year of diagnosis, TNM stage, HER2
status and histologic grading, were shown in Table 1.
Adjuvant chemotherapy was completed in 16.7% of the 252
patients with high recurrent risks; thirty-nine (33.3%) patients
received adjuvant radiotherapy.
4. The completion rate and the time of discontinuation of
oral endocrine therapy in elderly patients
One hundred and thirty-three patients took a complete course
of oral adjuvant ET. The completion rate of adjuvant oral ET was
49.4% in the intention-to-treat patients in our study, which would
increase to 56.7% if only patients willing to initiate ET were taken
into account. Neither patients with a larger tumor size (T2-T4),
positive lymph node involvement, higher histologic grade (grade 2/3), positive HER2 status, known systemic disease, of younger age,
nor a complete adjuvant chemotherapy showed a signiﬁcantly
higher completion rate (p ¼ 0.08, 0.46, 0.27, 0.12, 0.50, 0.46, and
0.87, respectively, using the Chi-square test). However, patients
with a completed adjuvant radiotherapy presented with a signiﬁ-
cantly higher rate of a complete ET: 58.8% versus 27.4, p ¼ 0.04.
Ninety-eight patients (37.4%) had an ET duration of less than 5
years, 64 patients (24.8%) took oral endocrine agents less than two
years, and 38 patients (14.1%) never initiated medication at all
(Table 2).
Twenty-six of the 98 patients had an early discontinuation due
to recurrence: there were 14 patients with distant metastasis and
12 with local recurrence. Most distant metastatic events (71.4%)
occurred within the initial two years. Of the other 72 patients with
early discontinuation of ET, only seven patients (9.7%) had well-
documented ET-related adverse events in the medical records, 24
patients (33.3%) refused to take ET but remained in follow-up, 9
patients (12.5%) were attributed to other medical conditions, and
32 patients (44.4%) were lost in follow-up before a complete ET
period (Table 3).
Table 2
The duration of endocrine therapy (ET) for elderly patients.
Duration of ET 0 months <6 months 6 months
<2 years
2 years
<5 year
A full coursea
Number of patients (%) 38 (14.1) 22 (8.2) 42 (16.6) 34 (12.6) 133 (49.4)
Reasons of discontinuation
Undocumented 38 16 23 20 e
Recurrence 0 3 15 9 e
Other medical conditions 0 3 3 3 e
Hot ﬂash 0 1 0 0 e
Osteoporosis 0 0 0 1 e
Thromboembolic events 0 0 1 1 e
a “A full course” means a ﬁve-year treatment for the majority of patients, except 4 patients diagnosed before 1996 with a two-year treatment.
Table 3
The initial oral endocrine agent and it completion rate.
The initial oral endocrine agent Tamoxifen (n ¼ 198) Aromatase inhibitor (n ¼ 33)
Upfront therapy (n ¼ 163) Switch to aromatase inhibitor (n ¼ 35)
Complete treatment n ¼ 87 (53.4%) n ¼ 27 (79.4%) n ¼ 19 (57.6%)
 Stroke, n ¼ 1
 Vaginal spotting, n ¼ 3
 Hot ﬂash, n ¼ 1
 Stroke, n ¼ 2
 DVTb, n ¼ 3
 Angina, n ¼ 1
 Vaginal spotting, n ¼ 8
 Osteoporosis, n ¼ 2
 LFTd elevation, n ¼ 1
 DCISc, n ¼ 1
 Arthralgia, n ¼ 2
Early discontinuation n ¼ 76 n ¼ 8 n ¼ 14
 Not documented, n ¼ 15
 LOFa, n ¼ 32
 Recurrence, n ¼ 20
 Angina, n ¼ 1
 CVA, n ¼ 1
 Hot ﬂash, n ¼ 1
 Other medical condition
- Colon cancer, n ¼ 1
- PPUe, n ¼ 1
- Retroperitoneal hematoma, n ¼ 1
- Diabetes mellitus, n ¼ 1
- Hyperparathyroidism, n ¼ 1
- Wound infection, n ¼ 1
 Not documented, n ¼ 5
 Recurrence, n ¼ 2
 Osteoporosis, n ¼ 1
 Not documented, n ¼ 4
 Arthralgia, n ¼ 3
 Recurrence, n ¼ 4
 Other medical conditions
- Lung cancer, n ¼ 1
- Colon cancer, n ¼ 1
- Bladder cancer, n ¼ 1
a LOF: loss of follow-up.
b DVT: deep vein thrombosis.
c DCIS: ductal carcinoma in situ.
d LFT: liver function test.
e PPU: perforated peptic ulcer.
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Of the 197 patients who initiated ET with tamoxifen, the
completion rate was 57.6%. Thirty-ﬁve patients (17.3%) switched to
AI from six months to three years after tamoxifen initiation. Fifteen
(44.1%) of the patients with switch were attributed to tamoxifen-
related thromboembolic events (stroke, angina, or deep vein
thrombosis) or endometrial thickening/vaginal spotting. When
patients switched to AI, the completion rate was signiﬁcantly
higher, 79.4% vs. 53.3% for patients with upfront tamoxifen treat-
ment (p ¼ 0.005 by the Chi-square test). Among the patients taking
aromatase inhibitor as the initial treatment, the completion rate
was 57.6% (Table 3).
6. Discussion
The completion rate of adjuvant endocrine therapy in HR-
positive breast cancer in our study was 49.4%, which was similar
to previous studies.11,12 After patients were excluded for refusing to
initiate ET, the overall completion rate further increased. We
generally have observed that cancer patients with poor prognostic
factors might exhibit improved medical compliance because of theawareness of a potentially poor outcome. To our surprise, this
perceptionwas not observed in our elderly patients. In fact, some of
the elderly patients might be less concerned about a poor cancer-
related outcome due to limited life expectancy; therefore, they
were reluctant to adhere to a pill regimen for ﬁve years. Further, the
completion rate among patients with known systemic disease was
not signiﬁcantly lower than those without such a disease. We can
hypothesize that oral ET was tolerable to elderly patients with
systemic comorbidities, so comorbidities were not a determinant
factor to adherence of oral ET. What's more, the completion of
chemotherapy did not correlate to an adherence with oral ET. As we
had believed, the toxicity proﬁle of chemotherapy, like fatigue,
neutropenia, diarrhea or microsites, was less favored than that of
oral ET.We can conclude that those patients that tolerated adjuvant
chemotherapy but not oral ET should not be attributed to the
adverse events of oral ET but were likely due to a poor insight of its
survival beneﬁts. On the contrary, patients who went through a
ﬁve-week radiotherapy demonstrated a signiﬁcant higher
completion rate of oral ET. We suggested that the patients with a
complete radiotherapy had a greater probability of continuing a
“long but durable” treatment like oral ET. Therefore, for elderly
patients who cannot complete or refuse adjuvant radiotherapy, we
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beneﬁts of oral ET.
In excess of 40% of patients with early discontinuation stopped
taking oral ET due to loss of outpatient follow-up. Thus, we cannot
identify why they were not willing to continue their breast cancer
follow-up. Furthermore, more than 10% of patients did not even
attempt ET after surgery. The two primary reasons why patients
may have failed to continue ET therapy were that patients were not
provided an adequate overview of the beneﬁts of ET, as well as
possible concerns about drug-related adverse events. Therefore, we
have suggested that physicians could improve patient adherence to
adjuvant ET by better educating their patients about both the sur-
vival beneﬁts of the ﬁve-year treatment, as well as the early
detection of drug-related discomforts.
The switch therapy in our study showed a signiﬁcantly higher
completion rate than upfront tamoxifen treatment. In the upfront
group, we noted that some patients could undertake ET, even if ET-
related adverse event occurred, while others could not. This can be
explained by the wide variety of frailties and comorbidities among
elderly patients. However, in the complete treatment group with
switch therapy, the identiﬁed tamoxifen-related adverse events
exceeded the upfront ones. Therefore, were elderly patients in the
switch group healthier than their counterparts in the upfront
tamoxifen group? Although we did not show such a similarity by
way of the Charlson comorbidity index and performance status in
this study, the higher completion rate could be explained by a kind
of “mental comfort” with the switch therapy. Once tamoxifen-
related adverse events occurred, they could recur again if patients
continued taking the same drug. However, patients were willing to
go on ET with another agent, like AI in this study, believing they
would not encounter another tamoxifen-related adverse events yet
still retain the survival beneﬁts. This could explain why the
completion rate was higher in the switch therapy than in the
tamoxifen upfront group. According to the BIG 1e98 study,13 switch
therapy presented similar survival beneﬁts with letrozole upfront
therapy, regardless of the nodal status. We can concluded that,
since the switch therapy in our study showed a higher completion
rate, elderly people would derive more survival beneﬁts from
switch therapy than upfront therapy.
Our study had several limitations. First, it was a retrospective
study and datawas derived from primary chart review. Accordingly,
much of the patient clinical information was unavailable, and the
medical staff did not always provide the detailed records that we
needed such as the reason for early withdrawal and patient per-
formance status. In fact, many withdrawal events were found
without a well-documented reason shown on medical records.
Second, the underestimation of ET-related adverse events in this
study is signiﬁcant. Nearly one-third of patients discontinued
endocrine therapy directly by failing to later visit our outpatient
services department. Consequently, we cannot precisely evaluate
the causes of discontinuation in these patients.
Based on the results of this retrospective study, we concluded
that the completion rate of oral endocrine therapy in our studywas similar to the completion rate in previous studies. Addition-
ally, the switch method of adjuvant oral endocrine therapy
demonstrated a better tolerance of and adherence by elderly
breast cancer patients, compared with tamoxifen or aromatase
inhibitor alone.Conﬂict of interest
The authors whose names are listed certify that they have no
afﬁliations with or involvement in any organization or entity with
any ﬁnancial interest (such as honoraria; educational grants;
participation in speakers' bureaus; membership, employment,
consultancies, stock ownership, or other equity interest; and expert
testimony or patent-licensing arrangements), or non-ﬁnancial
interest (such as personal or professional relationships, afﬁliations,
knowledge or beliefs) in the subject matter or materials discussed
in this manuscript.References
1. Cuzick J, Sestak I, BaumM, et al. Effect of anastrozole and tamoxifen as adjuvant
treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Lancet Oncol. 2010;11:1135e1141.
2. Regan MM, Price KN, Giobbie-Hurder A, et al. Interpreting Breast International
Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing
letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal
women with hormone receptor-positive, early breast cancer. Breast Cancer Res.
2011;13:209.
3. van de Velde Cornelis JH, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and
exemestane in early breast cancer (TEAM): a randomized phase 3 trial. Lancet.
2011;377:321e331.
4. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast
cancer: an overview of the randomised trials. Lancet. 1998;351:1451e1467.
5. Davies C, Pan HC, Godwin J, et al. Long-term effects of continuing adjuvant
tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen
receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:
805e816.
6. Gray RG, Rea D, Handley K, et al. aTTom: long-term effects of continuing
adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women
with early breast cancer. J Clin Oncol. 2013;31(suppl; abstr 5).
7. Freyer G, Braud AC, Chaibi P, et al. Dealing with metastatic breast cancer in
elderly women: results from a French study on a large cohort carried out by the
‘Observatory on Elderly Patients’. Ann Oncol. 2006;17:211e216.
8. Tew WP, Muss HB, Kimmicket GG, et al. Breast and ovarian cancer in the older
woman. J Clin Oncol. 2014;32:2553e2561.
9. Biganzoli L, Wildiers H, Oakman C, et al. Management of elderly patients with
breast cancer: updated recommendations of the International Society of
Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists
(EUSOMA). Lancet Oncol. 2012;13:e148ee160.
10. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypesddealing with
the diversity of breast cancer: highlights of the St Gallen International Expert
Consensus on the primary therapy of early breast Cancer in 2011. Ann Oncol.
2011;22:1736e1747.
11. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of
elderly women with breast cancer. J Natl Cancer Inst. 2000;92:550e556.
12. Kiderlen M, de Glas NA, Bastiaannet E, et al. Impact of comorbidity on outcome
of older breast cancer patients: a FOCUS cohort study. Breast Cancer Res Treat.
2014;145:185e192.
13. The BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence
with tamoxifen in women with breast Cancer. N Engl J Med. 2009;361:
766e776.
